Given the very very high liklihood of positive Phase 3 data on Aryplase, the fact that BMRN has identified almost half of the 500 (they're over 1000 so there's upside) patients necessary to reach $100MM in sales for Aryplase, and the fact that Phenoptin is basically a re-egnineered version of an existing drug that has a boat load of clinical data - I don't get it.
Also, just playing off the multiples of Aldurazyme and Aryplase sales combined, which by 2007-8 should gross to BMRN over $150-200MM, this baby is trading at grotesquely low levels. (w/o Phenoptin or Pheylase approved)
Once we get into April/May and Aryplase news comes out along with Phenoptin trial results and the start of a P/2 trial later in the year, we'll be back above 10. Afterall above $10 is only a $650M market cap. Pretty reasonable if you ask me.